Andrew Barnell

Andrew Barnell is the co-founder and CEO of Geneoscopy, a St. Louis life sciences company that turned a sibling conversation about a missed colonoscopy into ColoSense, the first FDA-approved stool RNA test for colorectal cancer screening. A Cornell economics graduate and Wharton MBA who started in J.P. Morgan's healthcare investment banking group and private equity at Lindsay Goldberg, Barnell paired his finance background with the scientific work of his sister and co-founder Erica Barnell, MD/PhD, to build a company that has raised more than $217 million and earned FDA approval for a noninvasive screening test built on patented RNA biomarker technology.